SCHEDULE: Janus Henderson Boosts Madrigal Pharma Stake to 9.9%

Janus Henderson Group plc has disclosed an increased beneficial ownership of 9.9% in Madrigal Pharmaceuticals, Inc. common stock as of June 30, 2025.

Summary

• Janus Henderson Group plc reported beneficial ownership of 2,191,753 shares of Madrigal Pharmaceuticals, Inc. common stock.
• This represents 9.9% of the total class of securities.
• The filing is an Amendment No. 6 to a Schedule 13G, indicating an update to previously reported ownership.
• The ownership is held with shared voting power and shared dispositive power over all 2,191,753 shares.
• Janus Henderson Group plc is classified as an Investment Adviser (IA) and a Parent Holding Company (HC).
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Madrigal Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It indicates a significant institutional stake.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Increased institutional ownership by Janus Henderson Group plc could signal confidence from a major investment firm, potentially influencing other investors and market perception.

Key Dates

Keywords

Madrigal Pharmaceuticals, Janus Henderson, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Investment Adviser, Pharmaceutical, Biotech